← Research library

Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Randomized study in people · 2009

What was studied
567 treated participants with type 2 diabetes and symptomatic polyneuropathy
Main finding
Neuropathic symptoms improved versus placebo. The vibration-threshold coprimary analysis over time did not reach statistical significance, although the final-visit comparison did.

TSS exposure-adjusted difference · −0.56 points; 95% CI −0.85 to −0.27 · p=0.0003

Reported findings and study design

567 diabetic-neuropathy patients: Actovegin 281 versus placebo 286. Twenty IV infusions 2,000 mg/day, then oral 1,800 mg/day for 140 days; total 160 days.

Population or model 567 treated participants with type 2 diabetes and symptomatic polyneuropathy

Dose, route and schedule

Actovegin: 20 intravenous infusions at 2,000 mg/day, followed by oral treatment at 1,800 mg/day for 140 days in diabetic polyneuropathy.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
TSS exposure-adjusted difference−0.56 points; 95% CI −0.85 to −0.27p=0.0003
TSS baseline-to-day-160 difference−0.86 points; 95% CI −1.22 to −0.50p<0.0001
Vibration threshold, exposure-adjusted3% decrease; 95% CI 0–6%p=0.084
Vibration threshold at day 1605% decrease; 95% CI 1–9%p=0.017
NIS-LL sensory function−0.25; 95% CI −0.46 to −0.04p=0.021
Adverse-event incidenceNo between-group difference reported

The nonsignificant exposure-adjusted vibration endpoint is preserved alongside the significant end-of-study result.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Endpoint timing matters; these findings do not establish general nerve regeneration or benefit in healthy people. No difference in adverse-event incidence was reported during this trial.

Source details

Journal publication

Indexed citation and abstract checked; full methods and risk-of-bias appraisal remain incomplete.

Sources checked

Citation

Randomized trialEnglish abstract

Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes care

Study source ↗ · DOI 10.2337/dc09-0545 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards